Blockchain

Pi Squared Raises $12.5 Million in Seed Funding Led by Polychain Capital to Build a Universal ZK Circuit Powered by Proof of Proof

Champaign, Illinois, United States, July 2nd, 2024, Chainwire

 

Pi Squared, (Proof of Proof), announced the closure of their first capital raise. Led by Polychain Capital, the syndicate includes ABCDE, Bloccelerate, Generative Ventures, Robot Ventures, and Samsung Next. Angel investors include Shumo Chu, Harish Devarajan, Justin Drake, Sreeram Kanaan, Csongor Kiss, George Lambeth, Yilong Li, Calvin Liu, Lucian Mincu, Karthik Raju, and Common Prefix.

Using zero-knowledge (ZK) technology in a correct-by-construction and fundamentally unique way, Pi Squared will enable trustless remote computing, AI, and interoperable smart contracts for any blockchain or dApp. This will be made possible through the creation of a universal and disarmingly small ZK circuit that checks the integrity of mathematical proofs, which will provide verifiable-computing correctness guarantees to all languages and virtual machines (VMs) alike directly from their formal semantics, without any translation to a common language, VM, or instruction set architecture (ISA).

“Our mission is to revolutionize verifiable computing, making it universal for all languages and virtual machines, inherently correct-by-construction, and lightning-fast,” says Grigore Roșu, CEO of Pi Squared and CS Professor at University of Illinois Urbana-Champaign. “This will have many applications, including a universal settlement layer (USL) so all Blockchains, L1s and L2s, can be universal, correct, inter-operable and efficient. It does not end there, our long-term mission is to settle all science and knowledge on USL.”

“Pi Squared’s proof of proof technology will have a transformative impact across Web3 and beyond,” said Karthik Raju, GP at Polychain Capital. “Pi Squared’s universal ZK circuit will significantly increase the reach and applicability of Web3 for everyone, from builders to end users.”

Pi Squared will enable the next generation of verifiable computing that is universal and scalable with an optimally minimal trust base. The first product powered by Pi Squared is the Universal Settlement Layer (USL), an architecture for modular blockchains that enables the following characteristics:

Universality

Computations can be expressed in any high-level or virtual machine language, without the need for compilers or translators.

Provable correctness

Computations verified by the USL are mathematically proven to be correct, and any external entity can independently verify the correctness of the state of the USL.

Trust Base Minimality

USL exposes any trust assumptions in upper-layer computations for increased transparency, end-user awareness, and will minimize the trust base through correctness proofs.

App Interoperability

The USL will support interoperability between different application modules and networks (e.g. appchains).

Determinism and reproducibility

The validation is reproducible and independently verifiable by any external entity.

Pi Squared’s USL therefore provides end-to-end correctness guarantees for generic computations while minimizing the trust base underlying these computations. USL promotes verifiable computing as the standard distributed computing paradigm without requiring or promoting particular domain-specific languages (DSLs), VMs, or execution environments, all while being efficient and scalable.

Pi Squared will be presenting and exhibiting at events around EthCC in Brussels from July 8th to 11th. Attendees can listen to Pi Squared’s CEO, Grigore Roșu, speak at Restaking & Infra Day on July 8th and L2con on July 9th.

About Pi Squared

Pi Squared means ZK proofs of mathematical proofs. Pi Squared uses ZK technology in a correct-by-construction and fundamentally unique way. A universal and disarmingly small ZK circuit provides verifiable-computing correctness guarantees to all languages and VMs alike, without any translation to a common language, VM, or ISA. Pi Squared is led by UIUC professor Grigore Rosu, founder of the K framework and of Runtime Verification, and consists of researchers and founders of successful projects in formal methods, blockchain, and AI/ML.

To book a meeting with Pi Squared’s CEO and team, attendees can reach out to [email protected].

To learn more about Pi Squared’s vision and Proof of Proof, visit pi2.network and follow Pi Squared on social media.

 

Contact

Head of Marketing
Chris Hazelton
Pi Squared Inc
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

2024-10-02T11:08:00Z

PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

  • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
  • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
  • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

Keiretsu Forum: A Global Leader in Early-Stage Innovation

Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

"Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

Event Details

  • Date: October 31, 2024
  • Time: 8:00 AM – 6:00 PM EDT
  • Location: Convene City View, 30 S 17th St, Philadelphia, PA

Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

About Keiretsu Forum :

Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

About Dr. Martin Gershon

Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

For media inquiries, please contact:

Cindi Sutera
AMS Communications
[email protected]
610-613-2773


GlobeNewsWire News

Recent Comments